cardiovascular benefits of semaglutide in Cardiometabolic Diseases: SELECTing the Target Population Semaglutide: A Game-Changer In Managing

Lower Inflammatory Markers Some research has shown decreases in markers like CRP (C-reactive protein) when GLP-1 therapies are used, indicating a calming effect on systemic inflammation

[DOI] [PubMed] [Google Scholar] 66.Makino H., Tanaka A., Asakura K., et al

The role of these new GLP-1 RAs in PCOS patients appears promising but safety, availability, insurance coverage, and cost must be better evaluated

Changes in gut microbiota control inflammation in obese mice through a mechanism involving Glp-2-driven improvement of gut permeability

Gradual, sustainable habits are key to long-term success, rather than relying on quick fixes